Brief: Corbus Pharmaceuticals Presents Latest Pre-Clinical Data On Crb-601

Corbus Pharmaceuticals Holdings

17/04/2023 13:34

April 17 (Reuters) - Corbus Pharmaceuticals Holdings Inc
 CRBP.O :
    * CORBUS PHARMACEUTICALS PRESENTS LATEST PRE-CLINICAL DATA
ON
CRB-601 AT THE 2023 AMERICAN ASSOCIATION FOR CANCER RESEARCH
ANNUAL MEETING
    * CORBUS PHARMACEUTICALS : CRB-601 SHOWS DOSE-DEPENDENT
ANTITUMOR
ACTIVITY CORRELATING WITH INCREASED BINDING TO ΑVΒ8 IN
PRE-CLINICAL TUMOR MODELS
    * CORBUS PHARMACEUTICALS HOLDINGS INC: CRB-601 ENHANCES
ANTI-PD-1
IMMUNOTHERAPY EFFICACY AND INDUCES LONG-LASTING TUMOR-SPECIFIC
CYTOTOXIC T-CELLS
    * CORBUS PHARMACEUTICALS HOLDINGS INC: IND SUBMISSION FOR
CRB-601
ON TRACK FOR 2H 2023

Source text for Eikon:  ID:nPn2pZbjZa 
Further company coverage:  CRBP.O